InvestorsHub Logo
Followers 79
Posts 24352
Boards Moderated 1
Alias Born 09/08/2000

Re: None

Wednesday, 07/19/2017 8:46:59 AM

Wednesday, July 19, 2017 8:46:59 AM

Post# of 27255
NVAX - 1.45 Pre-market now at 1.50/1.51

Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM

GAITHERSBURG, Md. , July 17, 2017 /PRNewswire/ --  Novavax, Inc. (Nasdaq:NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017 , at 4:30 p.m. ET .  Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older).  In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults and well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.